Obstetric implications of the factor V Leiden mutation: A review

被引:8
作者
Bloomenthal, D
Delisle, MF
Tessier, F
Tsang, P
机构
[1] Univ British Columbia, Childrens & Womens Hlth Ctr British Columbia, Dept Obstet & Gynaecol, Div Maternal Fetal Med, Vancouver, BC V6H 3N1, Canada
[2] Univ British Columbia, Childrens & Womens Hlth Ctr British Columbia, Dept Med, Div Hematol, Vancouver, BC V6H 3N1, Canada
[3] Ambulatory Care Clin, Vancouver, BC, Canada
关键词
factor V Leiden; thrombophilia; pregnancy complications;
D O I
10.1055/s-2002-20172
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Factor V Leiden (FVL) is a newly discovered genetic mutation that impairs one of the body's naturally occurring anticoagulation systems. The result is resistance to activated protein C and a predisposition to thrombosis. FVL is the most common cause of primary and recurrent venous thromboembolism in the pregnant and nonpregnant state. The FVL gene is common in the general population and transmitted in an autosomal dominant fashion. When FVL is combined with the prothrombotic state of pregnancy, the result is an increased propensity to manifest a number of pregnancy complications. These include recurrent pregnancy loss and stillbirth, severe and early-onset preeclampsia, placental abruption and possibly, intrauterine growth restriction. It remains unknown whether thromboprophylaxis is effective in ameliorating these pregnancy complications. The current literature and management recommendations are highlighted in this article.
引用
收藏
页码:37 / 47
页数:11
相关论文
共 64 条
[1]  
*ACOG, 2000, ACOG PRACT B, V19
[2]  
Arias F, 1998, J Matern Fetal Med, V7, P277
[3]   Current concepts of anticoagulant therapy in pregnancy [J].
Barbour, LA .
OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 1997, 24 (03) :499-&
[4]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[5]   Arg(506)-Gln mutation in factor V and risk of thrombosis during pregnancy [J].
Bokarewa, MI ;
Bremme, K ;
Blomback, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (02) :473-478
[6]   Perinatal aspects of inherited thrombophilia [J].
Bonnar, J ;
Green, R ;
Norris, L .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1999, 25 (05) :481-485
[7]   Activated protein C resistance can be associated with recurrent fetal loss [J].
Brenner, B ;
Mandel, H ;
Lanir, N ;
Younis, J ;
Rothbart, H ;
Ohel, G ;
Blumenfeld, Z .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (03) :551-554
[8]   Safety of withholding heparin in pregnant women with a history of venous thromboembolism. [J].
Brill-Edwards, P ;
Ginsberg, JS ;
Gent, M ;
Hirsh, J ;
Burrows, R ;
Kearon, C ;
Geerts, W ;
Kovacs, M ;
Weitz, JI ;
Robinson, KS ;
Whittom, R ;
Couture, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (20) :1439-1444
[9]   Guidelines for the management of thrombophilia [J].
Cavenagh, JD ;
Colvin, BT .
POSTGRADUATE MEDICAL JOURNAL, 1996, 72 (844) :87-94
[10]   FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C [J].
DAHLBACK, B ;
CARLSSON, M ;
SVENSSON, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) :1004-1008